1. AstraZeneca COVID-19 vaccine not recommended in adults under 55 in Canada

   News item 03 April 2021 Pages: 1 - 1

2. Diuretic-related eye disorders

   News item 03 April 2021 Pages: 2 - 2

3. No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine

   News item 03 April 2021 Pages: 3 - 3

4. Ongoing evaluation of COVID-19 Vaccine AstraZeneca-related blood clots

   News item 03 April 2021 Pages: 4 - 4

5. Package inserts to be digitalised in Japan from August 2021

   News item 03 April 2021 Pages: 5 - 5

6. Should oral amiodarone and sildenafil be contraindicated?

   News item 03 April 2021 Pages: 6 - 6

7. TNF-alpha inhibitors: potential risk of mycosis fungoides

   News item 03 April 2021 Pages: 7 - 7

8. Certain medicines in elderly can interfere with thyroid function tests

   News item 03 April 2021 Pages: 8 - 8

9. FDA warns propylhexedrine abuse or misuse may cause serious AEs

   News item 03 April 2021 Pages: 9 - 9

10. Hydroxyprogesterone caproate during pregnancy: cancer in offspring?

    News item 03 April 2021 Pages: 10 - 10

11. Systematic review: cardiotoxicity of immune checkpoint inhibitors

    Clinical study 03 April 2021 Pages: 11 - 11

12. Vasomotor symptoms with various tamoxifen doses

    Clinical study 03 April 2021 Pages: 12 - 12

13. Other adverse reaction research

    News item 03 April 2021 Pages: 13 - 13

14. Abacavir/dolutegravir/lamivudine

    Case report 03 April 2021 Pages: 14 - 14

15. Acetylcysteine/paracetamol

    Case report 03 April 2021 Pages: 15 - 15

16. Aciclovir

    Case report 03 April 2021 Pages: 16 - 16

17. Adalimumab

    Case report 03 April 2021 Pages: 17 - 17

18. Adalimumab

    Case report 03 April 2021 Pages: 18 - 18

19. Adalimumab

    Case report 03 April 2021 Pages: 19 - 19

20. Adalimumab

    Case report 03 April 2021 Pages: 20 - 20

21. Adalimumab/golimumab/infliximab

    Case report 03 April 2021 Pages: 21 - 21

22. Adalimumab/ixekizumab/secukinumab

    Case report 03 April 2021 Pages: 22 - 22

23. Afatinib

    Case report 03 April 2021 Pages: 23 - 23

24. Afatinib/gefitinib/pembrolizumab

    Case report 03 April 2021 Pages: 24 - 24

25. Alectinib/ceritinib/crizotinib

    Case report 03 April 2021 Pages: 25 - 25

26. Alendronic acid

    Case report 03 April 2021 Pages: 26 - 26

27. Alendronic acid/ibandronic acid

    Case report 03 April 2021 Pages: 27 - 27

28. Alendronic-acid

    Case report 03 April 2021 Pages: 28 - 28

29. Allopurinol

    Case report 03 April 2021 Pages: 29 - 29

30. Allopurinol

    Case report 03 April 2021 Pages: 30 - 30

31. Allopurinol

    Case report 03 April 2021 Pages: 31 - 31

32. Allopurinol/febuxostat

    Case report 03 April 2021 Pages: 32 - 32

33. Alteplase

    Case report 03 April 2021 Pages: 33 - 33

34. Amiodarone/atorvastatin/tafamidis meglumine interaction

    Case report 03 April 2021 Pages: 34 - 34

35. Amiodarone/fluconazole interaction

    Case report 03 April 2021 Pages: 35 - 35

36. Amisulpride/clozapine/fluoxetine interaction

    Case report 03 April 2021 Pages: 36 - 36

37. Amitriptyline/sodium bicarbonate

    Case report 03 April 2021 Pages: 37 - 37

38. Amphotericin-B/paracetamol

    Case report 03 April 2021 Pages: 38 - 38

39. Andexanet-α/heparin interaction

    Case report 03 April 2021 Pages: 39 - 39

40. Antianaemics

    Case report 03 April 2021 Pages: 40 - 40

41. Antibacterials

    Case report 03 April 2021 Pages: 41 - 41

42. Antibacterials/penicillins

    Case report 03 April 2021 Pages: 42 - 42

43. Antiepileptic drugs/rabies vaccine

    Case report 03 April 2021 Pages: 43 - 43

44. Antihistamines/corticosteroids/epinephrine

    Case report 03 April 2021 Pages: 44 - 44

45. Antihyperlipidaemics/antiplatelets/sirolimus

    Case report 03 April 2021 Pages: 45 - 45

46. Antihypotensives/antihypertensives/hydrocortisone

    Case report 03 April 2021 Pages: 46 - 46

47. Antineoplastics

    Case report 03 April 2021 Pages: 47 - 47

48. Antineoplastics

    Case report 03 April 2021 Pages: 48 - 48

49. Antineoplastics

    Case report 03 April 2021 Pages: 49 - 49

50. Antineoplastics

    Case report 03 April 2021 Pages: 50 - 50